Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupASX:EBO +0.91%80 Return-on-Tangible-Asset is 5.48% as of Dec. 2025, which is 18% below its 10-year median of 6.66. GuruFocus rates ASX:EBO with a GF Score™ of 80/100 and a GF Value™ of A$31.56 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Ebos Group ranks better than 71.19% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ebos Group's annualizedNet Income for the quarter that ended in Dec. 2025 was A$252 Mil. Ebos Group's average total tangible assets for the quarter that ended in Dec. 2025 was A$4,598 Mil. Therefore, Ebos Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 5.48%.
The historical rank and industry rank for Ebos Group's Return-on-Tangible-Asset or its related term are showing as below:
ASX:EBO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.96 Med: 6.66 Max: 7.38
Current: 5.14
During the past 13 years, Ebos Group's highest Return-on-Tangible-Asset was 7.38%. The lowest was 4.96%. And the median was 6.66%.
ASX:EBO's Return-on-Tangible-Asset is ranked better than 71.19% of 118
companies
in the Medical Distribution industry
Industry Median: 2.34
vs ASX:EBO: 5.14
Ebos Group (ASX:EBO) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Ebos Group Return-on-Tangible-Asset Related Terms
Ebos Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Ebos Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, CAH, COR: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Ebos Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Ebos Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 5.48% mean?
Ebos Group (ASX:EBO) has a Return-on-Tangible-Asset of 5.48% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ebos Group and its competitors. This is 18% below median its historical median of 6.66. Over the past decade, Ebos Group's Return-on-Tangible-Asset has ranged from 4.96 to 7.38. According to the industry distribution chart, Ebos Group ranks #34 out of 118 companies in the Medical Distribution industry, placing it in the top 28.8%.
Is Ebos Group's Return-on-Tangible-Asset too high?
Ebos Group's current Return-on-Tangible-Asset of 5.48% is 18% below median its 10-year median of 6.66. Over the past 10 years, this metric has ranged from a low of 4.96 to a high of 7.38. The Medical Distribution industry median Return-on-Tangible-Asset is 2.34. Ebos Group's value of 5.48% is 134.2% above this industry median. Based on the distribution chart, Ebos Group ranks #34 out of 118 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Return-on-Tangible-Asset compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #34 out of 118 companies for Return-on-Tangible-Asset. This puts Ebos Group in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.34. Ebos Group's value of 5.48% is 134.2% above this benchmark. Historically, Ebos Group's own Return-on-Tangible-Asset has ranged from 4.96 to 7.38 over the past decade. While the company's 10-year median is 6.66 vs. the industry median of 2.34, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.34, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Return-on-Tangible-Asset of 5.48% is 134.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Return-on-Tangible-Asset is 5.48%, which is 18% below median its own 10-year median of 6.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.56, compared to a current price of A$18.85 — trading 40.3% below its estimated fair value. The current Return-on-Tangible-Asset is 5.48%, which is 18% below median its 10-year median of 6.66 and 134.2% above the Medical Distribution industry median of 2.34. Ebos Group's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Return-on-Tangible-Asset is 5.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$18.85 is trading 40.3% below its estimated GF Value™ of A$31.56.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Return-on-Tangible-Asset: 5.48% (18% below median its 10-year median of 6.66)
GF Value™: A$31.56 vs. price of A$18.85 (40.3% below fair value)
Industry Position: 134.2% above the Medical Distribution median (#34 of 118)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
80GF Score
Get the complete analysis for ASX:EBO
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
